Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

121
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
121
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

31
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
31
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

57
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
57
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

36
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
36
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

32
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
32

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Ocular Penetration - Management of Ophthalmic Trauma].

Klinische Monatsblatter fur Augenheilkunde·2026
Same author

Dropless after cataract surgery (DACS): concepts, evidence and clinical potential.

Eye (London, England)·2026
Same author

Correction: Intravenous thrombolysis for acute central retinal artery occlusion: Protocol for a systematic review and individual participant data meta-analysis of randomized controlled trials.

PloS one·2026
Same author

Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON.

Ophthalmology and therapy·2026
Same author

Retinal layer reflectivity and thickness as OCT biomarkers for diagnosis and imaging-based stratification relative to the 4.5-h window in acute central retinal artery occlusion.

Frontiers in neurology·2026
Same author

Quantification of Specific Urinary Oligosaccharide Biomarkers for Diagnosis and Treatment Monitoring of Alpha-Mannosidosis.

Journal of inherited metabolic disease·2026

Related Experiment Video

Updated: May 7, 2026

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
11:03

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Published on: January 22, 2018

10.6K

Retinal Phenotype in Mucopolysaccharidosis Type III.

Emma Sieg1, Johannes Birtel2, Jan Wildner1

  • 1From the Department of Ophthalmology (E.S., J.B., J.W., N.G. M.S.S., Y.A.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

American Journal of Ophthalmology
|March 11, 2026
PubMed
Summary

Mucopolysaccharidosis type III (MPS III) patients show outer retinal layer degeneration, particularly in MPS IIIA. This study provides natural history data for future clinical trials and emphasizes the need for ophthalmological screening in MPS III.

More Related Videos

A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration
09:24

A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration

Published on: March 10, 2023

2.6K
Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

3.2K

Related Experiment Videos

Last Updated: May 7, 2026

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
11:03

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Published on: January 22, 2018

10.6K
A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration
09:24

A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration

Published on: March 10, 2023

2.6K
Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

3.2K

Area of Science:

  • Ophthalmology
  • Genetics
  • Rare Diseases

Background:

  • Mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome, is a rare genetic disorder causing neurocognitive decline and early death.
  • Visual impairment and retinal disease are common in MPS III, more so than in other MPS subtypes.

Purpose of the Study:

  • To characterize the retinal phenotype in MPS III using advanced imaging techniques.
  • To gain insights into the ocular disease progression in Sanfilippo syndrome.

Main Methods:

  • A retrospective case series included 27 patients with genetically confirmed MPS III (IIIA, IIIB, IIIC).
  • Spectral-domain optical coherence tomography (SD-OCT) analyzed retinal thickness and nerve fiber layer.
  • Best-corrected visual acuity, slit lamp microscopy, and fundoscopy were performed as feasible.

Main Results:

  • Parafoveal outer retinal layer degeneration was observed in 59% of patients.
  • Foveal thickening of the external limiting membrane was noted in 67% of patients.
  • MPS IIIA patients exhibited the most severe retinal abnormalities, including atrophy and fluid accumulation.

Conclusions:

  • A consistent pattern of parafoveal outer retinal degeneration exists across all MPS III subtypes.
  • MPS IIIA patients demonstrate the most significant retinal involvement, correlating with their rapid neurocognitive decline.
  • These findings support systematic ophthalmological examinations for MPS III patients and inform future clinical trial design.